The DOI matches its Crossref record; 94 of the 101 references it cites were found in a registry or an index.
Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:
Open accessAbstract
Background Cholinesterase (ChE) inhibitors currently used in the treatment of Alzheimer's disease (AD) are the acetylcholinesterase (AChE)-selective inhibitors, donepezil and galantamine, and the dual AChE and butyrylcholinesterase (BuChE) inhibitor, rivastigmine. In addition to differences in selectivity for AChE and BuChE, ChE inhibitors also differ in pharmacokinetic and pharmacodynamic properties, and these differences could significantly impact on safety, tolerability, and efficacy.Objective The aim of this article was to provide an overview of the ChE inhibitors widely used in AD, focusing on key pharmacologic differences among agents and how these may translate into important differences in safety, tolerability, and efficacy in clinical practice.Methods Using published literature collected over time by the author, a review was conducted, focusing on the pharmacology and clinical data of donepezil, galantamine, and rivastigmine.Results All ChE inhibitors have the potential to induce centrally mediated cholinergic adverse events (AEs), such as nausea and vomiting, if the dose is increased too rapidly or in increments that are too large. These AEs, which are most likely to occur during the "getting on," or dose-escalation, phase of treatment, may result in patients discontinuing treatment early without achieving optimum therapeutic benefit. To reduce the incidence of these AEs, a slow dose-escalation schedule has been established in clinical practice, consisting of a "start low, go slow" procedure with a minimum of 4 weeks between dose increases. After "getting on" treatment, maintaining treatment in the long term, or "staying on," may be achieved with good safety, tolerability, and sustained symptomatic efficacy across the key symptom domains (activities of daily living, behavior, and cognition).Conclusions ChE inhibitors provide symptomatic benefit in AD across key symptom domains. Factors influencing the safety, tolerability, and efficacy of these agents in clinical practice include ChE enzymes inhibited, brain and brain-region ChE selectivity, and metabolism route. Class-specific cholinergic AEs can be minimized using slow, flexible dose escalation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Rivastigmine can also hydrolyze the butyrylcholinesterase (BuChE) present at glial cells of the temporal cortex region of the brain [33].”
From Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer’s Disease Therapy (2021) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
J Neuropsychiatry Clin Neurosci
Yudofsky, S. C., & Hales, R. E. (1992) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.4.4.359 · Cited by 3,818
Arky, R. A. (1994) · Cited by 2,632
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Molecular and cellular biology of cholinesterases
Massoulié, J., Pezzementi, L., Bon, S., Krejci, E., & Vallette, F.-M. (1993) · Progress in Neurobiology · doi:10.1016/0301-0082(93)90040-y · Cited by 1,214
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
Inestrosa, N. C., Alvarez, A. R., Pérez, C. A., Moreno, R. D., Vicente, M., Linker, C., Casanueva, O. I., Soto, C. A., & Garrido, J. (1996) · Neuron · doi:10.1016/s0896-6273(00)80108-7 · Cited by 1,117
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
A 5-month, randomized, placebo-controlled trial of galantamine in AD
Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P. R., Lilienfeld, S., Ding, C., & the Galantamine USA- Study Group (2000) · Neurology · doi:10.1212/wnl.54.12.2269 · Cited by 915
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
The Molecular Forms of Cholinesterase and Acetylcholinesterase in Vertebrates
Massoulié, J., & Bon, S. (1982) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.05.030182.000421 · Cited by 818
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
Winblad, B. G., Engedal, K., Soininen, H. S., Verhey, F. R. J., Waldemar, G., Wimo, A. B., Wetterholm, A.-L., Zhang, R., Haglund, A., Subbiah, P., et al. (2001) · Neurology · doi:10.1212/wnl.57.3.489 · Cited by 721
Wilcock, G. K., Lilienfeld, S., & Gaens, E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1445 · Cited by 623
The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1
Burns, A. S., Rossor, M. N., Hecker, J. R., Gauthier, S. G., Petit, H., Möller, H. ‐., Rogers, S. L., & Friedhoff, L. T. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017126 · Cited by 585
CHANGES IN BRAIN CHOLINESTERASES IN SENILE DEMENTIA OF ALZHEIMER TYPE
Perry, E. K., Perry, R. H., Blessed, G., & Tomlinson, B. E. (1978) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1978.tb00545.x · Cited by 560
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients
Mohs, R. C., Doody, R. S., Morris, J. C., Ieni, J. R., Rogers, S. L., Perdomo, C. A., Pratt, R. D., & for the “312” Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.481 · Cited by 502
Corey-Bloom, J. (1998) · Medical Entomology and Zoology · Cited by 467
Albuquerque, E. X., Alkondon, M., Pereira, E. F. R., Castro, N. G., Schrattenholz, A. S., Barbosa, C. T. F., Bonfante-Cabarcas, R. A., Aracava, Y., Eisenberg, H. M., & Maelicke, A. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36503-6 · Cited by 437
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.3.390 · Cited by 408
Sleep Problems and Institutionalization of the Elderly
Pollak, C. P., & PERLICK, D. A. (1991) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879100400405 · Cited by 396
Cholinesterase Inhibitors in the Treatment of Alzheimer??s Disease
Nordberg, A. K., & Svensson, A. (1998) · Drug Safety · doi:10.2165/00002018-199819060-00004 · Cited by 381
Doody, R. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.427 · Cited by 362
Farlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J. (2000) · European Neurology · doi:10.1159/000008243 · Cited by 332
Polinsky, R. J. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80127-6 · Cited by 323
Alvarez, A. R., Alarcón, R., Opazo, C., Campos, E. O., Muñoz, F. J., Calderón, F. H., Dajas, F., Gentry, M. K., Doctor, B. P., Mello, F. G. D., et al. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-09-03213.1998 · Cited by 320
Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain
Mesulam, M., Guillozet, A., Shaw, P., & Quinn, B. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0462 · Cited by 314
Arendt, T., Brückner, M. K., Lange, M., & Bigl, V. (1992) · Neurochemistry International · doi:10.1016/0197-0186(92)90189-x · Cited by 314
Butyrylcholinesterase in the life cycle of amyloid plaques
Guillozet-Bongaarts, A. L., Mesulam, M. M., Smiley, J. F., & Mash, D. C. (1997) · Annals of Neurology · doi:10.1002/ana.410420613 · Cited by 313
Álvarez, A., Opazo, C., Alarcón, R., Garrido, J., & Inestrosa, N. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1245 · Cited by 308
Enz, A., Amstutz, R., Boddeke, H. W. G. M., Gmelin, G., & Malanowski, J. (1993) · Progress in brain research · doi:10.1016/s0079-6123(08)62429-2 · Cited by 301
Rogers, S. L., & Friedhoff, L. T. (1998) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(97)00079-5 · Cited by 293
Selectivity of Cholinesterase Inhibition
Weinstock, M. (1999) · CNS Drugs · doi:10.2165/00023210-199912040-00005 · Cited by 283
A new rating scale for dementia syndromes
Gottfries, C. G., Bråne, G., Gullberg, B., & Steen, G. O. (1982) · Archives of Gerontology and Geriatrics · doi:10.1016/0167-4943(82)90031-0 · Cited by 279
Reading, P., Luce, A., & McKeith, I. G. (2001) · Movement Disorders · doi:10.1002/mds.1204 · Cited by 269
Rogers, S. L., Doody, R. S., Pratt, R. D., & Ieni, J. R. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00067-5 · Cited by 268
Donepezil for Treatment of Dementia With Lewy Bodies: A Case Series of Nine Patients
Shea, C., MacKnight, C., & Rockwood, K. J. (1998) · International Psychogeriatrics · doi:10.1017/s1041610298005341 · Cited by 229
Giacobini, E., Spiegel, R., Enz, A., Veroff, A. E., & Cutler, N. R. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200089 · Cited by 222
Alzheimer's Disease: Biology, Diagnosis and Therapeutics
Hier, D. B. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00025 · Cited by 197
Barnes, C. A., Meltzer, J., Houston, F. P., Orr, G. W., McGann, K., & Wenk, G. L. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00180-9 · Cited by 193
Measurement of quality-of-life changes in patients with Alzheimer's disease.
Dejong, R. N., Osterlund, O. W., & Roy, G. W. (1989) · PubMed · Cited by 186
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Inglis, F. (2002) · PubMed · Cited by 181
Cholinesterases and Cholinesterase Inhibitors
Harrell, L. E. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.516 · Cited by 176
Colocalization of cholinesterases with ? amyloid protein in aged and Alzheimer's brains
Mor�n, M. A., Mufson, E. J., & Gómez‐Ramos, P. (1993) · Acta Neuropathologica · doi:10.1007/bf00334445 · Cited by 174
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months
Darreh‐Shori, T., Almkvist, O., Guan, Z. Z., Garlind, A., Strandberg, B., Svensson, A., Soreq, H., Hellström‐Lindahl, E., & Nordberg, A. K. (2002) · Neurology · doi:10.1212/wnl.59.4.563 · Cited by 154
Alzheimer's disease : biology, diagnosis, and therapeutics
Iqbal, K., & Disorders, R. (1996) · SDÜ Bilgi Merkezi · Cited by 153
Selective Inhibitors of Butyrylcholinesterase
Giacobini, E. (2001) · Drugs & Aging · doi:10.2165/00002512-200118120-00001 · Cited by 152
Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChR
Samochocki, M., Zerlin, M., Jostock, R., Groot‐Kormelink, P. J., Luyten, W. H. M. L., Albuquerque, E. X., & Maelicke, A. (2000) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2000.00310.x · Cited by 151
Long-Term Use of Rivastigmine in Patients With Dementia With Lewy Bodies: An Open-Label Trial
Grace, J., Daniel, S., Stevens, T., Shankar, K. K., Walker, Z., Byrne, E. J., Butler, S., Wilkinson, D. G., Woolford, J., Waite, J., et al. (2001) · International Psychogeriatrics · doi:10.1017/s104161020100758x · Cited by 138
Donepezil Use in Alzheimer Disease
Barner, E. L., & Gray, S. L. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.17150 · Cited by 135
Bryson, H. M., & Benfield, P. (1997) · Drugs & Aging · doi:10.2165/00002512-199710030-00007 · Cited by 134
Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease
Cutler, N. R., Polinsky, R. J., Srarnek, J. J., Enz, A., Jhee, S. S., Mancione, L., Hourani, J., & Zolnouni, P. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1998.tb00645.x · Cited by 123
Davidsson, P., Blennow, K., Andreasen, N., Eriksson, B., Minthon, L., & Hesse, C. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01586-5 · Cited by 111
Rösler, M., Retz, W., Retz‐Junginger, P., & Dennler, H. J. (1999) · Behavioural Neurology · doi:10.1155/1999/168023 · Cited by 109
Long-term effects of rivastigmine in moderately severe Alzheimer's disease
Doraiswamy, P. M., Krishnan, K., Anand, R., Sohn, H., Danyluk, J., Hartman, R. D., & Veach, J. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00326-8 · Cited by 108
A New Rating Scale for Dementia Syndromes
Gottfries, C. G., Bråne, G., & Steen, G. (2009) · Gerontology · doi:10.1159/000212588 · Cited by 102
Muñoz, F. J., & Inestrosa, N. C. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00468-8 · Cited by 91
Extrapyramidal Motor Signs in Clinically Diagnosed Alzheimer Disease
Ellis, R. J., Caligiuri, M. P., Galasko, D. R., & Thal, L. J. (1996) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199601020-00008 · Cited by 88
Kása, P., Papp, H., Kása, P., & Torok, I. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00335-3 · Cited by 88
Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain
Siek, G. C., Katz, L. S., Fishman, E. B., Korosi, T. S., & Marquis, J. K. (1990) · Biological Psychiatry · doi:10.1016/0006-3223(90)90524-6 · Cited by 83
Maclean, L. E., Collins, C., & Byrne, E. J. (2001) · International Psychogeriatrics · doi:10.1017/s1041610201007670 · Cited by 81
Gann, H., Feige, B., Hohagen, F., van Calker, D., Geiss, D., & Riemann, D. W. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01172-6 · Cited by 75
Poirier, J. (2002) · PubMed · Cited by 74
Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep
Riemann, D. W., Gann, H., Dreßing, H. R., Müller, W. E., & Aldenhoff, J. B. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90013-2 · Cited by 74
Identification and treatment of sleep problems in the elderly
Ancoli‐Israel, S., Poceta, J. S., Stepnowsky, C. J., Martin, J. L., & Gehrman, P. (1997) · Sleep Medicine Reviews · doi:10.1016/s1087-0792(97)90002-2 · Cited by 74
Blackard, W. G., Sood, G., Crowe, D. R., & Fallon, M. B. (1998) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199801000-00015 · Cited by 72
Parnetti, L., Amici, S., Lanari, A., Romani, C., Antognelli, C., Andreasen, N., Minthon, L., Davidsson, P., Pottel, H., Blennow, K., et al. (2002) · Neurological Sciences · doi:10.1007/s100720200086 · Cited by 72
Merello, M., Sabe, L., Teson, A., Migliorelli, R., Petracchi, M., Leiguarda, R. C., & STARKSTEIN, S. E. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.12.1503 · Cited by 68
Scali, C., Casamenti, F., Bellucci, A., Costagli, C., Schmidt, B. H., & Pepeu, G. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200090 · Cited by 65
Enz, A., Boddeke, H. W. G. M., Gray, J. A., & Spiegel, R. (1991) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1991.tb00232.x · Cited by 64
Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type
Agid, Y., Dubois, B., Anand, R., & Gharabawi, G. (1998) · Current Therapeutic Research · doi:10.1016/s0011-393x(98)85048-0 · Cited by 64
Adamis, D., & Ball, C. (2000) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(200003)15:3 · Cited by 63
Self-citationAcetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-β-peptides
Alvarez, A. R., Bronfman, F. C., Pérez, C. A., Vicente, M., Garrido, J., & Inestrosa, N. C. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(94)12127-c · Cited by 63
Molecular interactions of acetylcholinesterase with senile plaques
Inestrosa, N. C., & Alarcón, R. (1998) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(99)80002-3 · Cited by 61
Discontinuation syndrome following donepezil cessation
Singh, S., & Dudley, C. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.811 · Cited by 54
Lamb, H. M., & Goa, K. L. (2001) · PharmacoEconomics · doi:10.2165/00019053-200119030-00008 · Cited by 49
Weiser, M., Rotmensch, H. H., Korczyn, A. D., Hartman, R. D., Cicin-Sain, A., & Anand, R. (2002) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.599 · Cited by 46
Extrapyramidal Side Effects in a Patient Treated With Risperidone Plus Donepezil
Magnuson, T. M., Keller, B. K., & Burke, W. J. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1458a · Cited by 44
Amici, S., Lanari, A., Romani, R., Antognelli, C., Gallai, V., & Parnetti, L. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00314-1 · Cited by 41
Parkinsonism Onset in a Patient Concurrently Using Tiapride and Donepezil
Arai, M. (2000) · Internal Medicine · doi:10.2169/internalmedicine.39.863 · Cited by 39
Jhee, S. S., Shiovitz, T. M., Hartman, R. D., Messina, J. C., Anand, R., Sramek, J. J., & Cutler, N. R. (2002) · Clinical Neuropharmacology · doi:10.1097/00002826-200203000-00013 · Cited by 37
The effect of rivastigmine on sleep in elderly healthy subjects
Schredl, M., Weber, B., Braus, D. F., & Heuser, I. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00077-2 · Cited by 36
Foster, R. H., & Plosker, G. L. (1999) · PharmacoEconomics · doi:10.2165/00019053-199916010-00009 · Cited by 35
Soluble and membrane-bound forms of brain acetylcholinesterase in Alzheimer's disease.
Schegg, K., Harrington, L., Neilsen, S., Zweig, R., & Peacock, J. (1992) · Neurobiology of Aging · doi:10.1016/0197-4580(92)90092-c · Cited by 35
Pratt, R. D. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00266-6 · Cited by 32
Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., Griggio, S., & Bava, A. (2002) · Current Therapeutic Research · doi:10.1016/s0011-393x(02)80050-9 · Cited by 25
Rogers, S. H., Farlow, M., Doody, R. S., Mohs, R. C., & Friedhoff, L. I. (1998) · Cited by 25
Sweet, R. A., Akil, M., Mulsant, B. H., Ulrich, R. F., Pasternak, R. E., & Zubenko, G. S. (1998) · Journal of Neuropsychiatry · doi:10.1176/jnp.10.1.68 · Cited by 13
Svensson, A. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00213-8 · Cited by 8
Svensson, A., & Nordberg, A. K. (1996) · Neurobiology of Aging · doi:10.1016/s0197-4580(96)80616-6 · Cited by 5
528. Antiemetics mitigate nausea and vomiting in Alzheimer’s patients receiving rivastigmine
Cutler, N. R., Hartman, R. D., Messina, J. C., Anand, R., Sramek, J. J., & Jhee, S. S. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00798-8 · Cited by 4
Rizzo, J., Chang, S. J., & Cohen, A. (2001) · Value in Health · doi:10.1016/s1098-3015(11)71778-8 · Cited by 2
Research works printed but not linked: 10
- McRae, 1999, A large-scale, open-label trial of donepezil in the treatment of Alzheimer's disease: Side effects and concomitant medication use, Int J Neuropharmacol, 2, S176
- Shua-Haim, 2001, Safety and tolerability of slow titration of rivastigmine (Exelon) in the treatment of patients with Alzheimer's disease (AD): An overall analysis of two prospective studies, J Am Geriatr Soc, 49, S76
- Vellas, 1998, Interim results from an international clinical trial with rivastigmine evaluating a 2-week titration rate in mild to severe Alzheimer's disease patients, Int J Geriatr Psychopharmacol, 1, 140
- Schneider, 1998, Systematic review of efficacy of rivastigmine for patients with Alzheimer's disease, Int J Geriatr Psychopharmacol, 1, S26
- Anand, 2000, Dose-response effect of rivastigmine in the treatment of Alzheimer's disease, Int J Geriatr Psychopharmacol, 2, 68
- Cummings, 2000, Rivastigmine provides behavioural benefits to Alzheimer's disease patients residing in a nursing home: Findings from a 26-week trial, Neurology, 54, A468
- Sanders, 2001, Donepezil in dementia with Lewy bodies: Treatment and withdrawal, Int Psychogeriatr, 13, 224
- Raskind M, Truyen L. Galantamine has long-term cognitive benefits in Alzheimer's disease—an analysis of responder rates at 36 months. Poster presented at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; April 3–6, 2003; Geneva, Switzerland.
- Grossberg, 2001, Rivastigmine in Alzheimer's disease: Efficacy over 2 years compared with historical controls, Int Psychogeriatr, 13, 237
- Barber, 1996, Butyrylcholinesterase alters the aggregation state of Aβ amyloid, Proc Soc Neurosci, 22, 1172
Cited by
Sorted by citations
Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease.
Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108352 · Cited by 1,147
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654
Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Tryphena, K. P., Shukla, R., Khatri, D. K., & Vora, L. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102481 · Cited by 438
Flavonoids and their role in oxidative stress, inflammation, and human diseases
Jomová, K., Alomar, S. Y., Valko, R., Líška, J., Nepovimová, E., Kuča, K., & Valko, M. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111489 · Cited by 449
Expression and Function of the Cholinergic System in Immune Cells
Fujii, T., Mashimo, M., Moriwaki, Y., Misawa, H., Ono, S., Horiguchi, K., & Kawashima, K. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01085 · Cited by 385
Metadata
- Authors
- Grossberg, G. T.
- Affiliations
- Saint Louis University (US)
- Corresponding author
- Grossberg, George T
- ORCID
- Grossberg, George T
- Venue
- Current Therapeutic Research
- Publisher
- Elsevier BV
- Published
- 2003-04
- Volume
- 64
- Issue
- 4
- Pages
- 216-235
- ISSN
- 0011-393X (ISSN-L)
- PMC
- PMC4052996
- OpenAlex
- W170237590
- Cited by
- 384
- References
- 101
- Citations by year
- 2026: 26 · 2025: 45 · 2024: 72 · 2023: 41 · 2022: 28 · 2021: 27 · 2020: 20 · 2019: 24 · 2018: 19 · 2017: 14 · 2016: 11 · 2015: 7 · 2014: 3 · 2013: 7 · 2012: 5
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Current Therapeutic Research (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Pharma
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- cholinesterase inhibitors, Alzheimer's disease, donepezil, galantamine, rivastigmine, acetylcholinesterase inhibitors, butyrylcholinesterase inhibitors, dose escalation, safety and tolerability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
